12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MDT-637: Phase I data

The double-blind, placebo-controlled, U.S. Phase I Study MDT-637-CP-102 trial in healthy volunteers showed that multiple ascending-doses of MDT-637 were well tolerated with no significant adverse events or clinically significant changes in lung function reported. Additionally, MicroDose said MDT-637 was...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >